Moreover, the TLR9 agonist ODN1585 failed to significantly reduce the tumor burden and led to T cell decrease in the treated group compared with the control group (Figure 1B, Figure 5A-B, Figure S4A and C), which was consistent with the findings of clinical trials 16, 17. Here, TLR9 is linked to neoplasm.